CTAs keep buying Treasuries, gold longs face stop-loss risk: BofA
In recent transactions reported to the Securities and Exchange Commission, Topline Capital Management, LLC, led by its managing member Collin McBirney, disclosed the sale of Paysign, Inc. (NASDAQ:PAYS) common stock totaling $863,044. These sales occurred over two days, with shares sold at prices ranging from $3.06 to $3.24. According to InvestingPro data, the stock has seen a significant decline of over 41% in the past six months, though it maintains a market capitalization of $163 million.
On January 13, Topline Capital sold 154,982 shares at $3.06 each. The following day, an additional 120,000 shares were sold at $3.24 per share. Following these transactions, Topline Capital's holdings in Paysign decreased to 5,336,146 shares. InvestingPro analysis indicates the company currently trades below its Fair Value, with a "GREAT" overall financial health score.
The shares are held indirectly through Topline Capital Partners (WA:CPAP), LP, a Delaware limited partnership. While Topline Capital Management and McBirney are not directly listed as beneficial owners, they are associated with the shares through their roles in managing the partnership. For deeper insights into PAYS's valuation and financial metrics, access the comprehensive Pro Research Report available on InvestingPro, which covers over 1,400 US stocks with expert analysis and actionable intelligence.
In other recent news, Paysign, Inc. reported a robust 23% revenue growth in its third-quarter earnings call, reaching $15.3 million, alongside a 20.6% rise in adjusted EBITDA to $2.8 million. This growth was particularly driven by the company's patient affordability business. The company also announced plans to expand its program offerings and a new partnership with a leading pharmaceutical company. Despite challenges in the plasma business and ongoing legal expenses, Paysign maintains a positive outlook, expecting revenues between $56.5 million and $58.5 million and a net income guidance of $3 million to $3.5 million for the year. Furthermore, Paysign's patient affordability segment saw a significant surge with 66 active programs, and its plasma donor compensation revenue grew by 3.4% to $11.4 million. The company also revealed an anticipated year-over-year revenue growth of 20% to 24%. These are recent developments reflecting Paysign's financial performance and future expectations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.